A detailed history of Woodline Partners LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Woodline Partners LP holds 198,766 shares of ASND stock, worth $29.3 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
198,766
Previous 196,030 1.4%
Holding current value
$29.3 Million
Previous $29.6 Million 8.52%
% of portfolio
0.27%
Previous 0.28%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $331,247 - $420,441
2,736 Added 1.4%
198,766 $27.1 Million
Q1 2024

May 15, 2024

BUY
$123.45 - $159.4 $22.2 Million - $28.7 Million
179,881 Added 1113.88%
196,030 $29.6 Million
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $1.39 Million - $2.06 Million
16,149 New
16,149 $2.03 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $22 Million - $26.6 Million
209,683 Added 220.46%
304,796 $32.7 Million
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $11.6 Million - $15.3 Million
-116,280 Reduced 55.01%
95,113 $11.6 Million
Q3 2022

Nov 14, 2022

BUY
$84.03 - $110.23 $8.85 Million - $11.6 Million
105,267 Added 99.19%
211,393 $21.8 Million
Q2 2022

Aug 15, 2022

SELL
$78.08 - $117.61 $459,578 - $692,252
-5,886 Reduced 5.25%
106,126 $9.87 Million
Q1 2022

May 16, 2022

SELL
$102.18 - $135.75 $11.5 Million - $15.3 Million
-112,437 Reduced 50.09%
112,012 $13.1 Million
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $28.5 Million - $38.1 Million
224,449 New
224,449 $30.2 Million
Q1 2020

May 15, 2020

SELL
$97.01 - $145.11 $5.36 Million - $8.02 Million
-55,284 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$91.45 - $139.12 $5.06 Million - $7.69 Million
55,284 New
55,284 $7.69 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $8.22B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.